Credit Suisse AG lifted its holdings in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 7.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,715 shares of the biotechnology company’s stock after purchasing an additional 2,828 shares during the quarter. Credit Suisse AG owned 0.08% of Prothena worth $2,022,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in Prothena by 45.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 712 shares of the biotechnology company’s stock worth $35,000 after buying an additional 221 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Prothena by 84.8% during the first quarter. Nisa Investment Advisors LLC now owns 970 shares of the biotechnology company’s stock worth $47,000 after buying an additional 445 shares during the last quarter. Point72 Middle East FZE acquired a new position in Prothena during the fourth quarter worth $48,000. Lazard Asset Management LLC increased its holdings in Prothena by 61.1% during the first quarter. Lazard Asset Management LLC now owns 1,733 shares of the biotechnology company’s stock worth $63,000 after buying an additional 657 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Prothena by 16.6% during the first quarter. Tower Research Capital LLC TRC now owns 1,803 shares of the biotechnology company’s stock worth $88,000 after buying an additional 257 shares during the last quarter. Institutional investors own 97.08% of the company’s stock.
Insider Buying and Selling
In related news, insider Wagner M. Zago sold 19,000 shares of the company’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $71.06, for a total transaction of $1,350,140.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Wagner M. Zago sold 19,000 shares of the company’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $71.06, for a total transaction of $1,350,140.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Karin L. Walker sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $69.19, for a total transaction of $345,950.00. The disclosure for this sale can be found here. Insiders sold 87,333 shares of company stock valued at $5,904,733 over the last quarter. 28.20% of the stock is owned by company insiders.
Prothena Stock Performance
Prothena (NASDAQ:PRTA – Get Free Report) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.11). Prothena had a negative net margin of 244.45% and a negative return on equity of 25.43%. The business had revenue of $4.02 million during the quarter, compared to analyst estimates of $5.09 million. During the same quarter last year, the company posted ($0.88) earnings per share. The company’s revenue was up 206.3% on a year-over-year basis. On average, analysts forecast that Prothena Co. plc will post -2.99 EPS for the current year.
Analysts Set New Price Targets
PRTA has been the topic of several research reports. StockNews.com initiated coverage on shares of Prothena in a report on Thursday, August 17th. They issued a “hold” rating on the stock. JMP Securities upped their price objective on shares of Prothena from $82.00 to $83.00 and gave the company an “outperform” rating in a report on Friday, August 4th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Prothena in a report on Friday, August 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $129.00 price objective on shares of Prothena in a report on Tuesday, August 22nd. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Prothena currently has a consensus rating of “Moderate Buy” and an average target price of $87.56.
Check Out Our Latest Report on PRTA
Prothena Profile
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Articles
- Five stocks we like better than Prothena
- What is the Australian Securities Exchange (ASX)
- MarketBeat Week in Review – 8/28 – 9/1
- What is the S&P 500 and How It is Distinct from Other Indexes
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- 3 Best Fintech Stocks for a Portfolio Boost
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. plc (NASDAQ:PRTA – Free Report).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
